← DPP-4 inhibitors × all-cause mortality

RetractedSynthesisPloS one2025

RETRACTED: Cardiovascular and mortality outcomes of DPP-4 inhibitors vs. sulfonylureas as metformin add-on therapy in patients with type 2 diabetes: A systematic review and meta-analysis.

Refli Hasan et al.PubMed ↗Full text ↗Publisher ↗

  • DPP-4 inhibitors plus metforminlooks good hereFewer deaths, lower major heart events.Randomised, large.

What the trial testedrandomised · 505,821 people · 2025

Randomised vs sulfonylureas plus metformin

Reduced deaths

−21%−29% to −12%

DPP-4 inhibitors plus metformin vs sulfonylureas plus metformin

Bigger than 6 in 10 for all-cause mortality

As reported

RR 0.79, 95% CI 0.71–0.88 · the paper's word: all-cause mortality

Randomised vs sulfonylureas plus metformin

Lowered major heart events

−21%−27% to −16%

DPP-4 inhibitors plus metformin vs sulfonylureas plus metformin

Bigger than 5 in 10 for cardiovascular events

As reported

RR 0.79, 95% CI 0.73–0.84 · the paper's word: major adverse cardiovascular events

Who was studied, and how

505,821people with cardiovascular disease, in this paper

The trial randomly assignedassigned by chance

DPP-4 inhibitors plus metformin
sulfonylureas plus metformin

Reduced deaths−21%

Lowered major heart events−21%

randomised

the abstract, start to end

… cardiovascular events (risk ratio [RR]: 0.79; 95% confidence interval [CI]: 0.73-0.84; p < 0.001) and all-cause mortality (RR: 0.79; 95% CI: 0.71-0.88; p < 0.001) …

← favours treatmentfavours comparator →
could be chance
All-cause mortalityDPP-4 inhibitors plus metformin vs sulfonylureas plus metformin
RR 0.790.71–0.88
Major adverse cardiovascular eventsDPP-4 inhibitors plus metformin vs sulfonylureas plus metformin
RR 0.790.73–0.84
MetforminDPP-4 inhibitorsCardiovascular eventsAll-cause mortality
1 / 4

2 papers cite it

2025
this papercites it
Full record →Abstract, authors, funding and every citing paper · PMID 40323973